Introduction
Animal studies have shown that the sensitivity of blood vessels to the vasoconstrictor effects of angiotensin II appears to be modulated by the activity of the renin-angiotensin system with the vasoconstrictor response being enhanced when endogenous angiotensin II levels are reduced by angiotensin converting enzyme inhibition [1] , sodium loading [2] or nephrectomy [3] . Conversely, elevation of circulating angiotensin II levels by angiotensin II receptor antagonists [4] , sodium depletion [2] or renal artery stenosis [5] is associated with a diminished pressor response to infused angiotensin II.
In animal models angiotensin II down-regulates its receptor by reduction of receptor density. This has been demonstrated in the vasculature [1] , renal glomeruli [6] and hepatocytes [7] . Angiotensin II, however, positively modulates the expression of the receptor gene in the adrenal gland [8, 9] .
The recent identification of the ATi receptor isoforms (ATIa and ATIb) [10, 11] with differences in structure and tissue distribution (ATIb predominantly adrenal) may explain the differential receptor regulation which occurs in different tissues. The effect of angiotensin converting enzyme inhibitors (which lower circulating AII) and the newer angiotensin 11 antagonists (which raise circulating All) on angiotensin II receptor regulation needs to be established.
This study evaluated the effects of orally administered enalapril on angiotensin II induced vasoconstriction in the forearm.
Methods
The design chosen was a randomised, double-blind, placebo controlled, two way crossover study in Following each forearm study venous blood was drawn from the control arm after 2 h of lying supine for measurement of plasma angiotensin II (normal range 5-35 pg ml-'). The assay used was that described by Dusterdieck & McElwee [13] with minor modifications [14] .
Mean supine blood pressure recordings after 10 min rest were obtained on each study day using the Copal UA 751 semi-automatic oscillometric instrument [15] .
Compliance to the prescribed treatment regimen, was assessed by the following formula: ((tablets issued)-(tablets returned)/(tablets issued)) x 100. Percentage change in blood flow was calculated as: ( [16] .
It was estimated that eight subjects would give the study a power of 80% to detect a decrease in forearm blood flow of 30% between placebo and enalapril after the highest dose of angiotensin II, with significance being declared at the two sided 5% level. An estimate of between subject variability was obtained from analysis of data from a previous study [17] . It was assumed that the within subject crossover design would reduce the variance by a factor of two [18] .
Results are presented as mean ± s.e. mean. Responses were compared by analysis of variance and t-test. Differences were considered significant if P < 0.05.
Results
Forearm studies (Table 1) Blood flow in the non-infused control arm did not change significantly throughout the study on each day. On the control day angiotensin II produced a dose dependent decrease in forearm blood flow in the cannulated arm from a mean (± s.e. mean) baseline value of 3.46 ± 0.44 to 1.75 ± 0.2 ml 100 ml-' minat the highest dose (50 000 fmol min-1) (P < 0.01).
On placebo, angiotensin II produced a dose related decrease in forearm blood flow from a mean baseline of 4.27 ± 0.64 to 1.87 ± 0.39 ml 100 ml-' min-' at the highest dose (P < 0.01).
On enalapril, angiotensin II produced a dose related decrease in forearm blood flow from a mean baseline of 4.12 ± 0.46 to 1.83 ± 0.27 ml 100 ml-' min-' at the highest dose (P < 0.01). The reductions in blood flow on each study day were not significantly different from each other.
When responses were expressed as the percentage change in forearm blood flow (Figure 1 ) to correct for possible changes caused by extraneous factors such as altered level of arousal [16] , the conclusion that The mean (± s.e. mean) baseline angiotensin II level was 7.88 ± 1.1 pg ml-' (normal range 5-35 pg ml-') which did not differ significantly from placebo 7.4 ± 1.7 pg ml-'. The angiotensin II level was reduced significantly on treatment with enalapril 2.82 ± 0.44 pg ml-' (P = 0.004).
Blood pressure
The mean (± s.e. mean) baseline supine blood pressure was 129/76 ± 5/3 mm Hg. The mean (± s.e. mean) supine blood pressures at the end of the placebo and enalapril phases were 126/75 ± 5/1 mmHg and 113/71 ± 4/3 mmHg respectively. The reduction in systolic and diastolic pressures obtained with enalapril were statistically significant (P < 0.0001 and P < 0.01 respectively).
Compliance
Percentage compliance on enalapril and placebo was 92.8% and 94.6% respectively.
Discussion
The apparent inverse relationship between circulating angiotensin II levels and AT, receptor density in vascular smooth muscle [19] , is similar to that observed with other peptide hormones, such as insulin [20] , and growth hormone [21] . At a cellular level fluctuations in ambient angiotensin II concentration might influence the rates of receptor degradation and/or synthesis, thus changing total receptor number.
The main finding in the present study is that oral enalapril therapy for 2 weeks at a dose sufficient to reduce plasma angiotensin II and systemic blood pressure does not enhance the response to intra-arterial doses of angiotensin II in the forearm of salt replete healthy volunteers. Consequently despite a large body of in vitro and in vivo animal data to suggest that the vasoconstrictor response to angiotensin II is enhanced when endogenous angiotensin II levels are reduced the present findings argue against an appreciable up-regulation of ATI receptors in the human forearm vasculature with angiotensin converting inhibition in salt replete healthy subjects.
A within-group vasoconstrictor comparator such as noradrenaline may have been helpful in taking into account changes in the vessel wall reactivity and structure which may have occurred following a reduction of blood pressure and which may have altered the response to angiotensin II. As baseline blood flow was unchanged in each of the treatment groups it seems likely that the response to angiotensin II, however would more likely be increased by these mechanisms after treatment than unchanged as was the case in the present study.
There are a number of possible explanations as to why we did not see an enhanced response to infused angiotensin II with prior enalapril treatment. Firstly, species-specific differences in the organisation of the renin angiotensin system have emerged which suggest that direct cross-species extrapolations of the observations of the effects of ACE inhibition cannot necessarily be made. It may be that there is no mechanism relating ambient angiotensin II levels to ATI receptor regulation in man. Animal models of the mode of ACE inhibitor action must therefore be interpreted with caution.
Secondly, these were salt replete normal subjects whose initial baseline angiotensin II levels were within normal limits and as a consequence the absolute reduction in angiotensin II in response to angiotensin converting enzyme inhibition was not as great as tends to be seen in hyper-reninaemic states. It may be that with a greater and/or more prolonged reduction in endogenous angiotensin II levels that ATI receptor up-regulation may become more apparent.
In conclusion, this study in healthy salt replete subjects demonstrates that reduced plasma angiotensin II does not enhance the response to exogenous intra-arterial angiotensin II 
